1. Khan A, Schwartz K.
Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA Summary Basis of Approval reports.
Annals of Clinical Psychiatry, (In Press, 11/2005.)

2. Thase ME, Shelton RC, Khan A.
Treatment of SSRI nonresponders with venlafaxine extended release: a randomized comparison of standard and higher dosing strategies.
Journal of Clinical Psychopharmacology, (In press, 3/2006).

3. Alper K, Schwartz KA, Khan A.
Seizure risk among psychopharmacology clinical trial participants based on FDA SBA reports.
Biological Psychiatry, (In Press, 9/2006).